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Abstract
Introduction: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by microvascular damage,
inflammation, and fibrosis. It has become increasingly evident that platelets, beyond regulating hemostasis, are
important in inflammation and innate immunity. Platelets may be an important source of proinflammatory and
profibrotic cytokines in the vascular microenvironment. In this study, we sought to assess the contribution of
platelet-derived factors in patients with SSc to the angiogenesis of human dermal microvascular endothelial cells
(DMVECs) in a tubule formation assay and to characterize the secretion of profibrotic and proinflammatory
cytokines in these platelets.
Methods: We analyzed platelets obtained from 30 patients with SSc and 12 healthy control subjects. Angiogenesis
was evaluated in vitro with a DMVEC tubule formation assay on Matrigel and platelet-derived angiogenic factors
such as vascular endothelial growth factor (VEGF), 165b isoform (VEGF165b), and cytokine secretion was evaluated.
Platelet serotonin content was also determined.
Results: When DMVECs were incubated with SSc platelet releasates, tubule formation was significantly inhibited
(p < 0.01, t test), and higher expression of endothelin-1 in these cells was observed compared with control subjects
(p < 0.05, Mann–Whitney U test). In SSc platelet releasates, VEGF165b was significantly higher (p < 0.05, t test), and
the VEGF165b/VEGF ratio was increased compared with that of control subjects. Higher secretion of transforming
growth factor β (p < 0.01, t test) and CD40L (p < 0.01, t test) was observed compared with control subjects. Also,
intraplatelet serotonin levels were lower in platelets obtained from patients with diffuse SSc compared with
patients with limited SSc and control subjects (p < 0.05, t test).
Conclusions: Our findings suggest that antiangiogenic factors such as VEGF165b, together with proinflammatory
and profibrotic factors secreted by platelets, can contribute to the progression of peripheral microvascular damage,
defective vascular repair, and fibrosis in patients with SSc.
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Introduction
Systemic sclerosis (SSc), or scleroderma, is a chronic auto-
immune disease characterized by vasculopathy, immune de-
regulation, and fibrosis of the skin and internal organs. It
has an estimated prevalence of about 1–2 per 100,000 per-
sons [1]. Women are at much higher risk for developing
scleroderma, generally starting with symptoms in middle
age [2]. Clinically, the disease is classified into two major
subgroups according to the extension of skin involvement
(limited or diffuse cutaneous scleroderma) and the autoanti-
body profile. Both types can present with vascular involve-
ment, Raynaud’s phenomenon and obliterative vasculopathy,
and systemic fibrosis [3]. The pathogenic triad involving vas-
cular injury, autoimmunity, and fibrosis (scleroderma tri-
fecta) is classically considered a hallmark of the disease, but
the interplay among these distinct processes, which initiate
and sustain the progressive tissue damage in scleroderma,
requires further exploration [4–6]. Both autoimmunity and
vasculopathy appear to precede the onset of the disease, and
contribute to the progression of fibrosis.
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Platelets play key roles in hemostasis, thrombosis, and
tissue repair and, as more recently described, in inflam-
mation and innate immunity [7]. Platelets are currently
being used, among others, for regenerative treatments
after bone surgery and cosmetic surgery, although solid
evidence of their regulatory functions is missing. Endo-
thelial dysfunction and immune regulatory mechanisms
may be associated with platelet function. It has been
proposed that platelets can play a role in SSc because
enhanced activation and an increased tendency to aggre-
gation have been described in these patients [8].
Platelets could substantially contribute to the patho-
physiology of scleroderma through several mechanisms.
The levels of several platelet-derived molecules, such as
β-thrombomodulin and platelet-derived growth factor,
are elevated in the serum of patients with SSc [8, 9]. In
addition, elevated levels of circulating platelet aggregates
have been described [8]. Silveri et al. found higher levels
of endothelium-derived endothelin-1, tissue type plas-
minogen activator, plasminogen activator inhibitor type
1, and platelet-derived growth factor in patients with
Raynaud’s phenomenon associated with scleroderma
than in control subjects, suggesting platelet activation in
vivo and endothelial damage [10]. However, the exact
contribution of platelets and platelet-derived factors in
the pathogenesis of SSc and other fibrotic diseases has
not yet been established.
Our hypothesis is that platelets contribute to main-
taining the microvascular injury that leads to fibrosis in
patients with SSc. The aim of this study was to further
characterize the role of platelets in vascular damage in
patients with scleroderma and their proinflammatory
and profibrotic cytokine profiles. In particular, the angio-
genesis of human dermal microvascular endothelial cells
(DMVECs) was evaluated in the presence of platelet su-
pernatants obtained from patients with SSc. Also, anti-
angiogenic factors such as vascular endothelial growth
factor (VEGF), 165b isoform (VEGF165b), were assessed.
Serotonin content, cytokine secretion profile, and fibro-
blast proliferation and stimulation by SSc and control
platelets were also evaluated. Our results add further
evidence for the participation of platelets in microvascu-
lar damage and fibrosis induction in SSc.
Material and methods
Patients
We studied platelets derived from 30 patients with SSc,
including both women and men (mean 51.3 years), and
from 12 healthy control subjects. The diagnosis of SSc
was made according to the American College of Rheuma-
tology criteria [11], and the patients were classified into
diffuse and limited types according to the criteria de-
scribed by Le Roy et al. [12]. The clinical characteristics of
the patients are summarized in Table 1. All samples were
obtained after the patients and control subjects gave their
written informed consent in accordance with the Declar-
ation of Helsinki. The ethics committees of the Pontificia
Universidad Católica de Chile and Comisión Nacional de
Investigación Científica y Tecnológica (CONICYT) ap-
proved the entire study protocol. Patients and control sub-
jects taking aspirin or serotonin reuptake inhibitors were
excluded from the study.
Table 1 Demographic and clinical characteristics of patients
with SSc and control subjects
Characteristic Patients (n = 30) Control subjects
(n = 12)
Female sex, % 96.6 91.6
Age, yr, mean (SD) 51.3 (16.8) 41.9 (14.7)
Disease duration, mo, mean (SD) 128.5 (18.4)
Disease subset
Diffuse systemic sclerosis, % 17.2
Limited systemic sclerosis, % 82.8





Anti-RNA polymerase III 6.7
ESR, mm/h, mean (SD) 32.7 (33.6)
Hemoglobin, g/dl, mean (SD) 12.5 (1.2)
WBC, n/μl, mean (SD) 7288.21 (2836.6)
Platelets, 109/L, mean (SD) 245 (65)
CRP, mg/L, mean (SD) 0.47 (0.5)
Ultrasensitive CRP μg/ml, mean (SD) 12.24 (28.2) 5.08 (1.0)
Complement component C3, mg/dl,
mean (SD)
104.42 (20.2)
Complement component C4, mg/dl,
mean (SD)
17.42 (5.79)
Raynaud’s phenomenon, % 89.66
Gastrointestinal symptoms, % 75.0
Digital ulcers, % 31.3
Calcinosis, % 17.2
Lung fibrosis, % 23.3






ANA antinuclear antibodies, CRP C-reactive protein, ESR erythrocyte sedimentation
rate, IQR interquartile range, SD standard deviation, WBC white blood cell count
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Platelet isolation
Platelets were prepared as previously described [13].
Briefly, venous blood (40 ml) was collected from patients
and control subjects and diluted in acid citrate dextrose
formula A solution (1:10 vol/vol). After centrifugation
(10 minutes at 150 × g) the platelet-rich plasma was col-
lected and centrifuged (10 minutes at 150 × g). The pellet
was washed with Tyrode’s solution (137 mM NaCl,
5.3 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 4.1 mM
NaCO3, and 5.5 mM glucose, pH 6.5, containing 120
nM prostaglandin E1). Platelets were centrifuged to re-
move residual leukocytes and finally resuspended in the
same Ca2+-free buffer. Leukocyte contamination was
evaluated by fluorescence microscopy using propidium
iodide staining. Leukocyte counts were always less than
1/106 platelets. In addition, monocyte contamination
was evaluated by amplification of CD14 messenger RNA
(mRNA) in polymerase chain reactions (PCRs). Isolated,
washed platelets at 600,000/μl were incubated in the
presence or absence of 2 μg/ml equine collagen (collagen
reagent; Hormon-Chemie, Munich, Germany) for 5 minutes
at 37 °C in a four-channel PAP-4 aggregometer (Bio/Data,
Horsham, PA, USA). The slope and maximal platelet aggre-
gation were recorded for 5 minutes. Then platelet suspen-
sions were centrifuged at 10,000 × g for 5 minutes, and
supernatants were collected and stored at −80 °C until
processing.
Measurement of inflammatory mediators
Transforming growth factor β (TGF-β), CD40L, tumor ne-
crosis factor (TNF)-α, VEGF, and VEGF165b were measured
in platelet supernatants by using commercial quantitative
colorimetric sandwich enzyme-linked immunosorbent as-
says (ELISAs) (catalogue numbers DB100B, DCDL40,
DTA00C, DVE00, and DY3045, respectively; R&D Systems,
Minneapolis, MN, USA) and connective tissue growth fac-
tor (CTGF) was measured in platelet supernatants by using
another ELISA (catalogue number RHF461CKX; Antigenix
America, Huntington Station, NY, USA) according to the
manufacturers’ instructions. Concentrations were calcu-
lated using a standard curve generated with specific stan-
dards provided by the manufacturers. Samples for TGF-β
analysis were acid-activated with 1 N HCl. Optical density
was measured with a microtiter plate reader at 450 nm.
Each sample was measured in triplicate. von Willebrand
factor (VWF) was measured in serum by ELISA as de-
scribed previously [14].
Intraplatelet serotonin determination
Intraplatelet serotonin (5-hydroxytryptamine) was mea-
sured using a high-performance liquid chromatography
(HPLC) technique [15]. The HPLC system consisted of
Ultrasphere 5-μm ODS column, 250 × 4.6 mm (HiChrom,
Theale, UK), a Waters 515 HPLC pump (Waters, Milford,
MA, USA), a Rheodyne manual injector (Sigma-Aldrich, St.
Louis, MO, USA), an electrochemical detector (Waters
464), and EMPOWER software (Waters). A platelet sample
(20 μl) was injected for HPLC analysis, and the amount of
serotonin was calculated on the basis of a calibration curve.
Angiogenesis and fibroblast proliferation assays
To assess platelet-derived angiogenic and antiangiogenic
factors, in vitro tubule formation assays were performed
with human DMVECs [catalogue number CRL-4025;
American Type Culture Collection (ATCC), Manassas,
VA, USA] cultured in 24-well plates covered with Matri-
gel culture mix (BD Biosciences, San Diego, CA, USA).
Briefly, Matrigel (200 μl) was pipetted into culture wells
and polymerized for 30 minutes at 37 °C. Then
DMVECs that formed a small number of short tubular
structures when cultured alone were cultured in duplicate
in endothelial growth basal medium (EBM-2) supple-
mented with EBM-2MV SingleQuots (Lonza, Walkersville,
MD, USA) on 24-well plates. Each experiment was con-
ducted by pairing samples of platelet supernatants (10 %
vol/vol) derived from patients with SSc and from healthy
control subjects. As a control, DMVECs were sup-
plemented with VEGF (10 ng/ml) or cultured alone on
Matrigel. Cells were photographed at 6 h. The results were
quantified by measuring the total tube length in each well.
To assess platelet-derived TGF-β, human lung fibro-
blasts (WI-38, catalogue number CCL-75; ATCC) were
cultured in 24-well plates in Dulbecco’s modified Eagle’s
medium (DMEM) supplemented with 10 % fetal bovine
serum. For proliferation assays, fibroblasts were cultured
with 10 % vol/vol SSc or control platelet supernatant
and after 36 h and proliferation was assessed with the
CellTiter 96 Non-Radioactive Cell Proliferation Assay
[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium brom-
ide (MTT); Promega, Madison, WI, USA) according to the
manufacturer’s instructions. Briefly, after 36 h in fibroblast
culture, MTT was added to the cells, followed by incuba-
tion at 37 °C for 4 h. Then each well was incubated for 1 h
with solubilization stop solution, and absorbance was ana-
lyzed using an ELISA reader at 570 nm. Untreated fibro-
blasts were used as a negative control. The results were
normalized to untreated cells. Fibroblasts incubated with
5 ng/ml TGF-β were used as a positive control.
Quantitative real-time RT-PCR of endothelin-1 and α-smooth
muscle actin
Gene expression was quantified by performing TaqMan
real-time reverse transcription (RT)-PCR with a PRISM
7500 System (Applied Biosystems, Foster City, CA, USA).
Total RNA was isolated from DMVECs and fibroblasts with
TRIzol reagent (Life Technologies, Grand Island, NY, USA).
RT into complementary DNA (cDNA) was performed using
avian myeloblastosis virus reverse transcriptase (Promega),
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with random primers. A predeveloped RPL32 TaqMan gene
expression assay (Hs00851655-g1; Life Technologies) was
used to normalize for the amounts of loaded cDNA. Differ-
ences were calculated with the comparative cycle threshold
method for relative quantification. Endothelin-1
(Hs00174961-m1; Life Technologies) and α-smooth muscle
actin (α-SMA) (Hs00426835-g1; Life Technologies) gene ex-
pression was evaluated with TaqMan assays.
Statistical analyses
Statistical analyses were performed using SAS version 9.1
software (SAS Institute, Cary, NC, USA). Data are shown
as mean ± standard error of the mean or median and
range. A two-sided non-parametric Mann–Whitney U test
was used for independent samples, and Student’s t test
was performed for paired samples. Analysis of variance
(ANOVA) was used for multiple comparisons. p < 0.05
was considered statistically significant.
Results
DMVEC angiogenesis is inhibited by SSc platelet releasates
Tissue fibrosis is preceded by microvascular injury in
SSc, leading to a progressive loss of capillaries [16]. The
effect of platelet releasates in angiogenesis was studied
using a tubule formation assay with DMVECs cultured
in Matrigel for 6 h. The capacity of platelet releasates to
enhance tubular formation was expressed as the total
tube length in the culture. Figure 1a–b shows that the
conditioned medium from SSc platelets significantly
inhibited tubule formation in Matrigel cultures com-
pared with supernatants from healthy control platelets.
The graph shows the results of six different duplicate ex-
periments (p < 0.01, t test). We found no differences ac-
cording to disease subset (data not shown).
We also evaluated endothelin-1 mRNA expression in
DMVECs after 24 h of culture in medium (control) or
platelet releasates from healthy control subjects and pa-
tients with SSc. Endothelin-1 was upregulated after cul-
turing the cells for 6 h with SSc platelet supernatant
(Fig. 1c) (p < 0.05, Mann–Whitney U test for healthy control
vs. SSc platelet releasates). Moreover, the supernatants from
healthy control platelets reduced the endothelin-1 mRNA
expression compared with non-stimulated DMVECs.
Several studies have shown that VEGF expression is
markedly increased in the epidermis and dermis of pa-




Fig. 1 Systemic sclerosis (SSc) platelet releasate inhibits angiogenesis. a Representative images of Matrigel cultures of dermal human microvascular
endothelial cells (DMVECs) after 6 h in culture. Healthy control and SSc platelet supernatants were cultured at 10 % vol/vol. Left and right columns represent
different magnifications (magnification is 10x for the first column and 20x for the second column). b Capillary morphogenesis was quantified by measuring
the length of capillary projections (*p< 0.01, t test). Data are mean ± standard deviation of six duplicate experiments. c Endothelin-1 mRNA expression in
DMVECs after 24 h of culture in platelet-conditioned medium. Endothelin-1 was upregulated after the cells were cultured with SSc platelet supernatants
(p< 0.05, Mann–Whitney U test). NS non-stimulated, VEGF vascular endothelial growth factor
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are splice variants of VEGF with antiangiogenic effects,
one of them being VEGF165b. Increased VEGF165b has
been shown in serum and in skin biopsies of patients
with SSc [20]. Given that platelets contain high
amounts of VEGF, we measured the levels of VEGF165b
in platelet supernatants. As shown in Fig. 2a, SSc plate-
let supernatants contained significantly higher levels of
VEGF165b than healthy control platelet supernatants
(n = 12; p < 0.05, t test). The ratio of antiangiogenic
VEGF165b to total VEGF in platelet supernatants was
higher in patients with SSc than in control subjects, but
the difference did not reach statistical significance
(n = 12; p = 0.071, t test) (Fig. 2b). Taken together, these
results support an antiangiogenic role of VEGF165b in
microvascular damage.
Proinflammatory and profibrotic cytokines secreted by
SSc-derived platelets
The releasates (basal and postcollagen) obtained after
platelet isolation were analyzed for TGF-β, TNF-α, CTGF,
and CD40L levels (Fig. 3a, b). We observed significant in-
creases in basal TGF-β (p < 0.01, t test) and CD40L (p <
0.01, t test) secretion in platelets from patients with SSc
compared with those from healthy control subjects. After
collagen stimulation, platelets from patients with SSc also
secreted higher levels of TGF-β and CD40L, although the
differences were non-significant in this experimental set-
ting (p = 0.07 for TGF-β and p = 0.05 for CD40L, t tests).
The slight increases of TNF-α and CTGF in basal and acti-
vated supernatants of SSc platelets compared with super-
natants of control platelets were not statistically significant.
It has been suggested that platelet-derived serotonin can
stimulate extracellular matrix synthesis in interstitial fibro-
blasts [21]. This observation led us to measure intraplate-
let serotonin content in patients with SSc. As observed in
Fig. 4a, serotonin is significantly reduced in patients with
diffuse SSc compared with patients with limited SSc and
healthy control subjects (p < 0.05, t test). We also observed
increased levels of VWF, a biomarker of endothelial acti-
vation, in the serum of patients with SSc (Fig. 4b).
Fibroblast proliferation and α-smooth muscle actin
expression
Tissue fibrosis in SSc results from an increased release of
extracellular matrix from aberrantly activated fibroblasts
[16]. Therefore, we evaluated the effect of platelet relea-
sates in human fibroblast proliferation and α-SMA expres-
sion. Human lung fibroblasts were cultured in 24-well
plates in DMEM supplemented with 10 % vol/vol SSc or
healthy control platelet supernatant. Figure 5a shows that
SSc platelet releasate supernatants induced stronger fibro-
blast proliferation than healthy control platelet releasate
supernatants (p < 0.001, ANOVA; p < 0.05, t test; control
vs. SSc platelet groups). Also, we observed greater α-SMA
expression by fibroblasts cultured with SSc than by control
platelet releasates (p < 0.05, ANOVA).
Discussion
Platelets are best known for their role in hemostasis and
thrombosis, but they also play important roles in inflam-
mation, angiogenesis, and wound healing. Due to their
small size and permanent circulation, they are in close
proximity to and in continuous interaction with the endo-
thelium. The sprouting of new vessels and the activation
of fibroblasts stimulated by platelets within injured tissues
probably contribute to prevention of hemorrhage and ac-
celerated wound healing. However, when this remodeling
response occurs with no regulation or in the absence of an
injury stimulus, the integrity of the vessel and the tissue
surrounding it can be impaired. Some of the first evidence
Fig. 2 Antiangiogenic factors predominate in systemic sclerosis (SSc)
platelet releasates. a Vascular endothelial growth factor, 165b
isoform (VEGF165b), determination in platelet supernatants. We
observed significantly higher levels of VEGF165b in SSc platelet
supernatants (*p < 0.05, t test). b Total vascular endothelial growth
factor (VEGF) was evaluated in platelet supernatants, and a
relationship between VEGF165b and VEGF was established. SSc
platelets releasate showed increased levels of the antiangiogenic
factor VEGF165b
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that platelets could play a role in SSc pathogenesis was re-
ported by Kahaleh et al. [8], who showed elevated levels of
circulating platelet aggregates and higher levels of β-
thrombomodulin in patients with SSc.
Microvascular damage is an early event in scleroderma.
It involves small vessels, particularly arterioles. Immuno-
histochemical studies of skin biopsy samples at different
disease stages indicate that the initial injury affects endo-
thelial cells [22, 23] with loss of integrity of the endothelial
lining, where gaps between cells and vacuolization of
endothelial cell cytoplasm have been described [24]. These
endothelial alterations lead to microvascular dysfunction,
which may precede by many years the appearance symp-
toms and involvement of internal organs, when fibrosis
becomes evident [25]. Endothelial injury results in platelet
activation and release of cytokines. In this study, we ob-
served that platelets from patients with SSc, compared
with healthy control platelets, inhibited angiogenesis in a
microtubule formation assay using DMVECs. This angio-
static effect may be a contributing factor to microangiopa-
thy in patients with SSc. Consistent with this observation,
we detected increased expression of endothelin-1 in endo-
thelial cells incubated with SSc platelet supernatants [26]
and inhibition when the same cells were incubated with
releasates from normal platelets. We cannot be certain
which platelet releasate component might contribute to
these contrasting observations. Interestingly, the authors
of a recent report found that serum containing anti–endo-
thelial cell antibodies from patients with SSc induced
endothelin-1 secretion from microvascular endothelial
cells [27]. However, we did not test anti–endothelial cell
antibodies in our patients.
Several studies have shown that the expression of VEGF,
a major proangiogenic regulator, is increased in different
a b
Fig. 3 Systemic sclerosis (SSc) platelets secrete higher amounts of tumor necrosis factor (TNF)-α, CD40L, connective tissue growth factor (CTGF),
and transforming growth factor (TGF)-β cytokines. Basal and postcollagen proinflammatory cytokines TNF-α (a) and CD40L (b) profibrotic cytokines
CTGF and TGF-β were determined in platelet supernatants of patients with SSc and healthy control subjects. We observed higher levels of CD40L and
TGF-β in SSc platelets before collagen activation. *p < 0.01, t test
Fig. 4 a Intraplatelet serotonin levels are decreased in patients with
diffuse systemic sclerosis (SSc) compared with patients with limited SSc
(*p < 0.05, t test). b von Willebrand factor antigen (VWF:Ag) was
evaluated in serum of patients with SSc and healthy control subjects.
Higher levels are observed in patients with SSc (*p < 0.05, t test)
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cell types in the epidermis and dermis of these patients
[18] and that the circulating levels of VEGF are also sig-
nificantly increased in patients with SSc [17, 28]. However,
in SSc, angiogenesis is defective and the disease evolves
toward a progressive loss of capillary vessels. Interestingly,
the antiangiogenic splice variant VEGF165b is upregulated
in SSc skin and circulation [20, 29], and it was suggested
that profibrotic TGF-β may contribute to the switch from
proangiogenic to antiangiogenic VEGF isoforms [19]. The
higher concentration of VEGF165b in SSc platelet releasates
that we observed, which is consistent with those previous
reports, may contribute to angiogenesis inhibition and mi-
croangiopathy. It is well known that, among the more than
1000 proteins demonstrated in platelet releasates [30, 31],
platelets contain several angiogenesis regulatory proteins in
their α-granules. Angiogenesis is regulated by a highly sen-
sitive interplay of growth factors and inhibitors, and their
imbalance may lead to disease. In this regard, the increased
ratio of antiangiogenic to angiogenic VEGF isoforms ob-
served in these patients could be explained by increases in
the antiangiogenic splice variant VEGF165b. Furthermore,
researchers in a recent study found that the levels of C-X-
C motif chemokine ligand 4/platelet factor 4, which is
platelet-specific, and antiangiogenic and profibrotic che-
mokines are increased in patients with SSc and correlate
with the level of fibrosis as well as the occurrence and pro-
gression of pulmonary arterial hypertension [32].
Some of the assessed platelet cytokines were increased
in SSc. CD40L, a transmembrane protein of the TNF
family, is expressed not only by immune system cells but
also by activated platelets [33]. It is stored in platelets
and is externalized and secreted during platelet activa-
tion [34, 35]. We observed that CD40L secretion in
platelets from patients with SSc was significantly in-
creased compared with platelets of control subjects (p <
0.01, t test). We also found that TGF-β, a growth factor
released from activated platelets, was significantly higher
in platelet releasates from patients than in those from
control subjects. TGF-β stimulates angiogenesis, smooth
muscle cells, and connective tissue fibroblasts [36], pro-
moting the synthesis of collagens and matrix components
[37]. In this regard, platelets are the main source of these
molecules in the circulation [38–40], and the authors of
previous reports have described increased levels of serum
CD40L in scleroderma patients [41] and increased serum
TGF-β in patients with Raynaud’s phenomenon [10].
Platelets contain almost all of the circulating sero-
tonin, a vasoactive monoamine that is released upon
platelet activation and which has been found to be in-
creased in the plasma of patients with SSc [42]. We ob-
served that intraplatelet serotonin was decreased in
patients with diffuse SSc compared with patients with
limited SSc and healthy control subjects. Given that the
serotonin content of platelets increases as platelets age
in the circulation, this finding may be explained by a de-
creased platelet lifespan in the circulation with a conse-
quent increased turnover in diffuse SSc [43]. However,
this is also compatible with the notion of damaged
endothelium-mediated platelet activation and acceler-
ated removal of platelets from the circulation. In this re-
gard, TGF-β and serotonin have been observed to be
involved in fibrosis generation [21].
Normally, under the influence of appropriate stimuli,
fibroblasts or their progenitor cells synthesize collagens
and other extracellular matrix glycoproteins; secrete
growth factors, cytokines, and chemokines; express sur-
face receptors for these ligands; and undergo transdiffer-
entiation into myofibroblasts [44]. These are specialized
Fig. 5 Systemic sclerosis (SSc) platelet supernatant stimulates fibroblast
proliferation and α-smooth muscle actin (α-SMA) expression. a Human
fibroblast proliferation was evaluated using a 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide assay after 24 h culture alone [non-
stimulated (NS)] or with transforming growth factor (TGF)-β as well as with
platelet releasates from patients with SSc and from healthy control
subjects. The rightmost bar is a negative control and corresponds to
normal platelets. Higher proliferation was observed after incubation with
SSc platelet supernatants than with healthy control supernatants (*p<
0.05, Mann–Whitney U test). b In the same experiment, α-SMA expression
was evaluated in fibroblasts. Higher α-SMA expression was found in
fibroblasts incubated with SSc platelet releasates than with healthy control
releasates (*p< 0.05, analysis of variance). Expression was determined by
performing real-time polymerase chain reactions using TaqMan assays
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cells that arise from fibroblasts in response to TGF-β
stimuli, which express the cytoskeletal protein α-SMA and
synthesize collagens, tissue inhibitors of metalloproteases,
and other extracellular matrix components [45, 46]. Sev-
eral alterations in fibroblasts have been described in the
pathogenesis of scleroderma [25]. Our results show that
platelet releasates from patients with SSc stimulate human
fibroblast proliferation and increase α-SMA expression,
further contributing to disease progression.
Conclusions
Platelets are involved in several forms of pathologic angio-
genesis, tissue repair, and fibrosis. From this point of view,
our results highlight the role of platelets in SSc pathogen-
esis. Our findings suggest that antiangiogenic factors such
as VEGF165b, together with proinflammatory (CD40L) and
profibrotic (TGF-β) factors secreted by platelets, can con-
tribute to the defective angiogenesis and vascular repair in
SSc. A better understanding of how platelets transport and
deliver angiogenic, inflammatory and fibrotic regulatory
proteins, as well as their contribution to SSc development
and perpetuation, may have novel therapeutic implications.
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